Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Pliant Therapeutics announced its second-quarter 2026 financial results and a corporate update, highlighting strong enrollment in its FORTIFY Phase 1b trial for PLN-101095, an oncology drug. The company also reported positive Phase 1 biomarker data for PLN-101095 and appointed two seasoned oncology drug development …